OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

The Rationale to Combine Prexasertib With LY3300054 in Ovarian Cancer

February 11th 2020

Claire Manuszak, BS, discusses the rationale to combine prexasertib (LY2606368) and LY3300054 in patients with high-grade serous ovarian cancer.

Dr. Cercek on the Need for Treatment Options in KRAS-Mutated mCRC

February 11th 2020

Andrea Cercek, MD, discusses the need for treatment options in KRAS-mutated metastatic colorectal cancer (mCRC).

Dr. Furman on Acalabrutinib Monotherapy in CLL

February 11th 2020

Richard R. Furman, MD, discusses acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Goy the Evolution of Treatment in Relapsed/Refractory MCL

February 11th 2020

Andre Goy, MD, MS, discusses the evolution of treatment in relapsed/refractory mantle cell lymphoma.

Dr. Snyder on the Utility of Transplant in MPNs

February 11th 2020

David S. Snyder, MD, discusses the utility of transplant in myeloproliferative neoplasms.

Dr. Levy on Ongoing Research Evaluating the Use of Liquid Biopsies in Lung Cancer

February 8th 2020

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses ongoing research regarding the use of liquid biopsies in lung cancer.

Dr. Oh on Targeted Treatment in Metastatic Castration-Resistant Prostate Cancer

February 8th 2020

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, and deputy director of The Tisch Cancer Institute, discusses targeted treatment in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Kaplan on the Use of PI3K Inhibitors in Follicular Lymphoma

February 8th 2020

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in follicular lymphoma.

Dr. Ritchie on the Immunologic Impact of Long-Term Venetoclax/Ibrutinib in R/R MCL

February 8th 2020

David Ritchie, MD, PhD, discusses the immunologic impact of long-term venetoclax and ibrutinib in relapsed/refractory mantle cell lymphoma.

Dr. Duska on Primary Debulking Surgery in Ovarian Cancer

February 8th 2020

Linda R. Duska, MD, discusses primary debulking surgery in ovarian cancer.

Dr. Cercek on the Importance of Molecular Testing in CRC

February 8th 2020

Andrea Cercek, MD, discusses the importance of molecular testing in colorectal cancer.

Dr. DiNardo on Rationale to Combine Enasidenib and Azacitidine in AML

February 7th 2020

Courtney DiNardo, MD, MSCE, discusses the rationale to combine enasidenib (Idhifa) with azacitidine in acute myeloid leukemia.

Dr. Harding on the Goal of the IMbrave150 trial in HCC

February 7th 2020

James J. Harding, MD, discusses the goal of the phase III IMbrave150 trial in hepatocellular carcinoma (HCC).

Dr. Weinberg on the Role of Cetuximab in Metastatic CRC

February 7th 2020

Benjamin Weinberg, MD, discusses the role of cetuximab in treating metastatic colorectal cancer.

Dr. Neven on the Design of the MONALEESA-3 Trial in Advanced Breast Cancer

February 7th 2020

Patrick Neven, MD, outlines the design of the phase III MONALEESA-3 trial in hormone receptor–positive, HER2-negative advanced breast cancer.

Dr. Sharman on Remaining Challenges With BTK Inhibitors in CLL

February 7th 2020

Jeff Sharman, MD, discusses the question of BTK inhibitors in treating patients with chronic lymphocytic leukemia.

Dr. Brammer on the Role of Stem Cell Transplant in ALL

February 7th 2020

Jonathan E. Brammer, MD, discusses the role of stem cell transplant in acute lymphoblastic leukemia.

Dr. Hwang on the Evolution of Treatment in Metastatic CSPC

February 7th 2020

Clara Hwang, MD, discusses the evolution of treatment for men with metastatic castration-sensitive prostate cancer.

Dr. Backes on Quality of Life With PARP Inhibitors in Ovarian Cancer

February 7th 2020

Floor J. Backes, MD, discusses quality of life with PARP inhibitors for patients with ovarian cancer.

Dr. Braun on Frontline Immunotherapy in Advanced RCC

February 7th 2020

David A. Braun, MD, PhD, physician at Dana-Farber Cancer Institute and instructor of medicine at Harvard Medical School, discusses the use of immunotherapy in the frontline treatment of patients with advanced renal cell carcinoma (RCC).